INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?
Inspire Medical stock's 39.7% three-month surge is driven by the easing of reimbursement pressures, increasing Inspire V adoption and Project Horizon targeting longer-term expansion.
INSP - Inspire Medical Systems, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$60.30
DETAILS
HIGH:
$85.00
LOW:
$39.00
MEDIAN:
$60.00
CONSENSUS:
$60.30
DOWNSIDE:
3.30%
Stock News
Here's Why You Should Add INSP Stock to Your Portfolio Now
Inspire Medical's Inspire V adoption, clinical evidence and underpenetrated OSA market support growth despite coding and reimbursement headwinds.
Contrasting Medacta Group (OTCMKTS:MEDGF) & Inspire Medical Systems (NYSE:INSP)
Medacta Group (OTCMKTS:MEDGF - Get Free Report) and Inspire Medical Systems (NYSE: INSP - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, analyst recommendations, dividends and profitability. Earnings and Valuation This table compares Medacta
New Strong Buy Stocks for August 18th
ALGT, HMC, INSP, AII and ALL have been added to the Zacks Rank #1 (Strong Buy) List on August 18, 2026.
Assenagon Asset Management S.A. Increases Holdings in Inspire Medical Systems, Inc. $INSP
Assenagon Asset Management S.A. increased its position in Inspire Medical Systems, Inc. (NYSE: INSP) by 66.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 864,395 shares of the company's stock after acquiring an additional 344,221 shares during
Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?
Inspire Medical's vast sleep apnea opportunity, rising margins and debt-free balance sheet support patience as reimbursement issues weigh on procedures.
INSP Raises 2026 Outlook as Reimbursement Headwinds Start to Ease
Inspire Medical raised its 2026 outlook after a Q2 beat, as Inspire V mix and cost control offset weak U.S. procedure activity.
INSP's 28.1% Past-Month Rally Raises a Key Question for Investors
Inspire Medical shares jumped 28.1% as an earnings beat, raised 2026 guidance and estimate revisions offset reimbursement pressure.
Amundi Sells 107,792 Shares of Inspire Medical Systems, Inc. $INSP
Amundi trimmed its holdings in Inspire Medical Systems, Inc. (NYSE: INSP) by 29.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 256,830 shares of the company's stock after selling 107,792 shares during the period. Amundi owned about 0.89% of
Inspire Medical Q2 Earnings Beat Estimates, '26 View Raised, Stock Up
INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.
Inspire Medical Systems Analysts Raise Their Forecasts Following Strong Q2 Results
Inspire Medical Systems Inc (NYSE:INSP) on Monday reported better-than-expected second-quarter financial results and raised its FY26 guidance.
Inspire Medical Systems, Inc. (INSP) Q2 2026 Earnings Call Transcript
Inspire Medical Systems, Inc. (INSP) Q2 2026 Earnings Call Transcript
Inspire Medical Systems Q2 Earnings Call Highlights
Inspire Medical Systems NYSE: INSP reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting it to raise its full-year outlook for revenue, adjusted operating margin and adjusted earnings per share.
Compared to Estimates, Inspire (INSP) Q2 Earnings: A Look at Key Metrics
The headline numbers for Inspire (INSP) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Inspire Medical Systems (INSP) Q2 Earnings and Revenues Beat Estimates
Inspire Medical Systems (INSP) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to earnings of $0.45 per share a year ago.
Inspire Medical Systems, Inc. Announces Second Quarter 2026 Financial Results, Raised 2026 Guidance, and Strategic Growth Plan
Generated second quarter revenue of $200.6 million Second quarter diluted EPS of $0.01; adjusted diluted EPS of $0.14 Second quarter operating cash flow of $23.2 million Announced strategic growth plan designed to unlock and redeploy $30 million for growth initiatives MINNEAPOLIS, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the Company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended June 30, 2026. “Our second quarter results reflect the increased discipline and focus we are bringing to the business as we continue to support customers through the evolving coding and reimbursement environment and invest in the long-term adoption of Inspire therapy,” said Tim Herbert, Chairman and CEO of Inspire Medical Systems.
Inspire Medical Systems, Inc. $INSP Stake Boosted by Bank of Nova Scotia
Bank of Nova Scotia boosted its stake in shares of Inspire Medical Systems, Inc. (NYSE: INSP) by 49.8% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 60,000 shares of the company's stock after buying an additional 19,958 shares during
Inspire Medical Systems, Inc. Announces Appointment of Seasoned Medical Device Executive Michael H. Carrel to its Board of Directors
MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of seasoned medical device executive Michael H. Carrel to its Board of Directors effective July 20.
Inspire Medical Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inspire Medical Systems, Inc. - INSP
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Inspire Medical Systems, Inc. (NYSE: INSP).In August of 2025, contrary to the Company's repeated assurances that it had met all regulatory, technical, and commercial prerequisites for the launch of its Inspire V device, the Company disclosed that the launch faced an "elongate.
Inspire Medical Systems, Inc. Announces Retirement of Casey M. Tansey from its Board of Directors
MINNEAPOLIS, July 22, 2026 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the retirement of Casey M. Tansey from the Inspire Board after more than eighteen years of service, effective July 30.
Price Targets
Inspire Medical price target raised to $54 from $40 at Evercore ISI
$54.00
(was $62.78)
Evercore ISI
Inspire Medical price target raised to $62 from $54 at Truist
$62.00
(was $52.22)
Truist Financial
Inspire Medical Systems (INSP) PT Raised to $60 at RBC Capital
$60.00
(was $63.00)
Shagun Singh
·
RBC Capital
Inspire Medical price target raised to $75 from $65 at Stifel
$75.00
(was $52.22)
Stifel Nicolaus
Inspire Medical upgraded to Outperform from Perform at Oppenheimer
$85.00
(was $52.22)
Oppenheimer
Inspire Medical price target raised to $60 from $55 at Piper Sandler
$60.00
(was $52.22)
Piper Sandler
Inspire Medical price target raised to $59 from $54 at Baird
$59.00
(was $52.22)
Robert W. Baird
Inspire Medical assumed with Sell from Neutral at UBS
$39.00
(was $50.93)
Patrick Wood
·
UBS
Inspire Medical price target raised to $54 from $50 at Truist
$54.00
(was $52.28)
Truist Financial
Inspire Medical downgraded to In Line from Outperform at Evercore ISI
$40.00
(was $41.35)
Daniel Markowitz
·
Evercore ISI
BofA Securities Downgrades Inspire Medical Systems (INSP) to Underperform
$39.00
(was $44.74)
Summit Redstone Partners
Inspire Medical price target lowered to $50 from $64 at Truist
$50.00
(was $45.95)
Richard Newitter
·
Truist Financial
Inspire Medical price target lowered to $45 from $56 at RBC Capital
$45.00
(was $44.98)
RBC Capital
Inspire Medical price target lowered to $55 from $62 at Evercore ISI
$55.00
(was $45.56)
Evercore ISI
Inspire Medical price target lowered to $50 from $63 at Baird
$50.00
(was $54.84)
David Rescott
·
Robert W. Baird
Inspire Medical downgraded to Neutral from Overweight at Piper Sandler
$55.00
(was $54.84)
Adam Maeder
·
Piper Sandler
Inspire Medical price target lowered to $64 from $70 at Truist
$64.00
(was $57.59)
Truist Financial
Inspire Medical price target lowered to $56 from $68 at RBC Capital
$56.00
(was $54.92)
Shagun Singh
·
RBC Capital
Inspire Medical price target lowered to $70 from $85 at Mizuho
$70.00
(was $53.42)
Mizuho Securities
Inspire Medical price target lowered to $70 from $85 at Stifel
$70.00
(was $53.96)
Stifel Nicolaus